Today a behemoth in the domestic blood purification industry, Jafron Biomedical was established in 1989 and three decades later was ranked 177th on the Hurun China's Top 500 listing of Most Valuable Private Companies 2020.
Jafron mainly engages in the R&D, production, and marketing of biomaterials and medical devices. Major products include HA series hemoperfusion cartridges, BS bilirubin adsorption columns, and DNA immunoadsorption columns. Having earned CE, ISO, and Chinese GMP certifications, the items are sold to 5,400 large and medium-size hospitals in more than 60 countries.
In addition to headquarters at Science & Technology Park at the Technological Innovation Coast in Tangjiawan, Jafron is building the 95,318-sqm (24-acre) Jinding Industrial Park. This may become the world's largest and most advanced blood purification medical equipment and consumable production bases upon completion in 2023.
With Hubei and Tianjin bases, the enterprise will form a complete blood purification industrial chain and anticipates total output value of 10 billion yuan ($1.5 billion). By 2025, Jafron will create a unique whole-value chain of "product + services + finance + Internet" in the field of blood purification, according to the company vision.
Jafron Biomedical in Tangjiawan [Photo courtesy jafron.com]